When managing severe, treatment-refractory Hidradenitis Suppurativa exhibiting incomplete response to single biologic agents, what safety parameters, diagnostic biomarkers, and/or monitoring protocols govern your decision to utilize off-label dual targeted therapy (e.g., combining a JAK inhibitor with an IL-17 or TNF inhibitor)?
Recent JAAD Case Reports article: Kherallah et al., PMID 41446693
1 Answer
Mednet MemberInvited Expert
Dermatology · Geisinger Commonwealth Medical College
Answered on
Two different MOAs and, to my knowledge, no additive risk of AEs. A JAK inhibitor, of course, requires initial blood work and "periodic" lab monitoring after a 12-week assessment. To date, "periodic" is left to the prescriber's discretion. Another three months seems reasonable, and then again in 6 m...
Join for free or sign in to see the full answer